[6]Schmidt G, Gerlinger C, Juhasz-Böss I, et al. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76. [7]Xu H, Han Y, W...
[17] Scott M, Vandenberghe M, Scorer P, et al. Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. 2021 ASCO.1021. [18] Corgiat B, O'Shaughnessy J, LoRusso P, et ...
Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016;142(6):1369-76.Schmidt G, Gerlinger C, Juhasz-Boss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Muller E, Fehm T, Abel M, Stein S, Bohle...
[10]Gullo G,Bettio D,Torri V,Masci G,Salvini P,Santoro A.Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.Investig N Drugs.2009;27:179–83. [11]Chen H-L,Chen Q,Deng Y-C.Pathologi...
HER2,又名HER2/neu,c-erbB-2,表皮生长 因子受体(EGFR)家族成员; 原癌基因,位于17q21,编码相对分子量 185KD的跨膜糖蛋白(跨膜酪氨酸激酶受体, 表皮生长因子样分子),在细胞表面表达; 通过参与信号传道通路的一系列活动影响细 胞的增殖与分化。 HER2 受体跨膜二聚体的信号传导途径 生长因子(配体...
Dictionary, Encyclopedia and Thesaurus - The Free Dictionary13,892,779,287visits served TheFreeDictionary Google ? Keyboard Word / Article Starts with Ends with Text EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусский...
C-erbB-2原癌基因(HER2/neu)位于染色体17q21,该基因过表达同时ER及PR均为阴性,即为HER2阳性型乳腺癌。该型多见于绝经前患者,恶性程度高,预后较差,较早出现腋窝淋巴结转移,组织学分级多为Ⅱ级～Ⅲ级,按照TNM分期标准,肿瘤多为T4,且分期较晚。有研究显示,在亚洲女性乳腺癌患者中,HER2阳性型的比例高于西方的白人...
點數呢D悶野留返比醫生,你知佢點匯報得喇。一般佢會比一個叫c-erbB2 score你,有D報告寫HER2/neu,其實都係講同一樣野。佢有4個可能性:0,1+,2+,3+。呢度好多病友搞錯以為「+就等如陽性、等如係HER2型」,呢個係錯嘅。你可以睇成+代表有天線,數字先反影有幾多天線。最終就會係咁: ...
p185或p185neu是指neu基因的蛋白质产物。HER2为HER受体。“HER受体”是属于人表皮生长因子受体(HER)家族的受体蛋白酪氨酸激酶并且包括EGFR、HER2、HER3和HER4受体。HER受体通常将包含可结合HER配体的胞外结构域;亲脂性跨膜结构域;保守性胞内酪氨酸激酶结构域;和带有几个可以磷酸化的酪氨酸残基的羧基端信号传导...
The eligibility criteria for low HER2 expression in that study required an IHC score of 1+, or 2+ with negative ISH, in patients with metastatic breast cancer. This benefit in survival, observed in a subset of patients categorised as “HER2-low”, a designation introduced by the DB-04 ...